Manufacturing company IDEX (NYSE: IEX) announced better-than-expected revenue in Q2 CY2026, with sales up 6.4% year on year to $920.6 million. Guidance for next quarter’s revenue was optimistic at $931.4 million at the midpoint, 2.1% above analysts’ estimates. Its non-GAAP profit of $2.32 per share was 10.1% above analysts’ consensus estimates.
Is now the time to buy IEX? Find out in our full research report (it’s free for active Edge members).
IDEX (IEX) Q2 CY2026 Highlights:
- Revenue: $920.6 million vs analyst estimates of $905.4 million (6.4% year-on-year growth, 1.7% beat)
- Adjusted EPS: $2.32 vs analyst estimates of $2.11 (10.1% beat)
- Adjusted EBITDA: $258.3 million vs analyst estimates of $242.3 million (28.1% margin, 6.6% beat)
- Revenue Guidance for Q3 CY2026 is $931.4 million at the midpoint, above analyst estimates of $912.2 million
- Management raised its full-year Adjusted EPS guidance to $8.77 at the midpoint, a 3.8% increase
- Operating Margin: 21.7%, in line with the same quarter last year
- Organic Revenue rose 5% year on year (miss)
- Market Capitalization: $16.99 billion
StockStory’s Take
IDEX’s latest quarter was marked by solid performance, as the company exceeded Wall Street’s revenue and earnings estimates, prompting a positive market reaction. Management attributed these results to higher volumes from its growth platforms, particularly within the Health & Science Technologies (HST) segment, fueled by demand in data center, semiconductor, and space and defense end markets. CEO Eric Ashleman highlighted that “orders came in better than expected, growing 28% organically,” with HST organic order growth at 47%. The company also benefited modestly from U.S. tariff refunds, which provided some margin and earnings tailwind, but the underlying strength was driven by operational execution and robust demand across key markets.
Looking ahead, IDEX’s guidance reflects confidence in continued growth, with management emphasizing a strong backlog and visibility into future orders, especially in high-growth sectors like data centers and semiconductors. Ashleman noted that customers in these markets are securing capacity for upcoming years, allowing IDEX to make targeted investments in throughput and select capacity expansions. CFO Sean Gillen added that the company is increasing capital expenditures to support these growth areas, while also maintaining flexibility for bolt-on acquisitions. Management believes these factors, combined with ongoing application of the company’s 8020 operational model, will support sustained margin expansion and value creation.
Key Insights from Management’s Remarks
Management credited the quarter’s outperformance to surging demand in advanced technology markets, effective operational execution, and ongoing portfolio optimization.
- HST segment momentum: The Health & Science Technologies segment led the company, with growth driven by demand for components supporting data centers, semiconductor manufacturing, and space and defense applications. These end markets now represent over one-third of HST revenue, highlighting a strategic portfolio shift.
- Order book strength: Orders rose 28% organically, with double-digit growth across all segments. Management emphasized that customers in fast-growing sectors are placing orders further into the future, boosting backlog and providing improved visibility for capacity planning.
- Operational leverage and cost discipline: Adjusted EBITDA margin expanded, helped by both volume growth and productivity gains. Management noted that margin expansion in HST was supported by the integration of acquired businesses and cost discipline via the company’s 8020 resource allocation framework.
- Tariff refunds impact: U.S. tariff refunds slightly reduced organic growth but contributed positively to margins and adjusted EPS for the quarter. CFO Sean Gillen stated that these were a one-time benefit largely confined to Q2, with associated customer rebates also recognized in the quarter.
- Capital deployment priorities: The company increased capital expenditures to support growth in advantaged markets and maintained an active share repurchase program. Management signaled a continued focus on bolt-on acquisitions, especially those that complement its leading platforms in data center, semiconductor, and water technologies.
Drivers of Future Performance
IDEX’s outlook is shaped by ongoing demand in technology-driven sectors, disciplined capital deployment, and targeted investments in core platforms.
- Technology sector tailwinds: Management expects continued strength in data center, semiconductor, and space and defense markets to drive organic growth, with customers securing long-term capacity and recurring revenue streams increasing, especially in HST.
- Capacity investments and backlog: Increased capital expenditures are being directed toward expanding throughput in high-growth businesses, backed by a robust order backlog and growing customer commitments that extend into 2027 and beyond. This is expected to support volume leverage and margin expansion.
- Portfolio optimization and risk: The company will continue to apply its 8020 operational framework to focus resources on the highest-return areas while remaining cautious about uncertainties in industrial demand, geopolitical risks, and inflation. Management highlighted monitoring both direct and distributor-driven order flows for signs of broader industrial recovery.
Catalysts in Upcoming Quarters
In coming quarters, our team is watching (1) the pace at which demand in technology end markets continues to translate into sustained organic revenue growth, (2) margin performance as IDEX increases investment in capacity and integrates recent acquisitions, and (3) the resilience of traditional industrial and distributor-driven order flows amid macroeconomic uncertainty. Progress on capital deployment priorities and new product rollouts will also serve as important signposts for execution.
IDEX currently trades at $229.62, up from $224.65 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
High Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
